| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 802 | 2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 290 | 2022 |
| Double hit and double expressors in lymphoma: definition and treatment PA Riedell, SM Smith Cancer 124 (24), 4622-4632, 2018 | 186 | 2018 |
| Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial SS Neelapu, M Dickinson, J Munoz, ML Ulrickson, C Thieblemont, ... Nature medicine 28 (4), 735-742, 2022 | 177 | 2022 |
| Survival with axicabtagene ciloleucel in large B-cell lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine 389 (2), 148-157, 2023 | 110 | 2023 |
| Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation … A Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, GC Hildebrandt, ... The Lancet Oncology 23 (8), 1066-1077, 2022 | 91 | 2022 |
| Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, J Arnason, ... Blood, The Journal of the American Society of Hematology 139 (12), 1794-1806, 2022 | 87 | 2022 |
| Chimeric antigen receptor T cell therapy during the COVID-19 pandemic V Bachanova, MR Bishop, P Dahi, B Dholaria, SA Grupp, B Hayes-Lattin, ... Biology of Blood and Marrow Transplantation 26 (7), 1239-1246, 2020 | 73 | 2020 |
| Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults BA Derman, K Kordas, J Ridgeway, S Chow, W Dale, SM Lee, E Aguada, ... Blood advances 3 (22), 3488-3498, 2019 | 64 | 2019 |
| A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for … PA Riedell, C Walling, LJ Nastoupil, M Pennisi, RT Maziarz, JP McGuirk, ... Blood 134, 1599, 2019 | 63 | 2019 |
| Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma KR Carson, P Riedell, R Lynch, C Nabhan, TM Wildes, W Liu, A Ganti, ... Journal of geriatric oncology 6 (3), 211-218, 2015 | 60 | 2015 |
| Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma KM Sanfilippo, TF Wang, BF Gage, S Luo, P Riedell, KR Carson Thrombosis research 143, 86-90, 2016 | 59 | 2016 |
| Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant M Scordo, TP Wang, KW Ahn, Y Chen, S Ahmed, FT Awan, A Beitinjaneh, ... JAMA oncology 7 (7), 993-1003, 2021 | 52 | 2021 |
| Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL) SS Neelapu, M Dickinson, ML Ulrickson, OO Oluwole, AF Herrera, ... Blood 136, 49, 2020 | 51 | 2020 |
| Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas PA Riedell, WT Hwang, LJ Nastoupil, M Pennisi, JP McGuirk, RT Maziarz, ... Transplantation and cellular therapy 28 (10), 669-676, 2022 | 49 | 2022 |
| Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy DY Xiao, S Luo, K O'Brian, A Ganti, P Riedell, KM Sanfilippo, RC Lynch, ... American journal of hematology 91 (10), 1002-1007, 2016 | 46 | 2016 |
| Rapid undetectable MRD (uMRD) responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with lisocabtagene … T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, ... Blood 134, 503, 2019 | 37 | 2019 |
| Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy … T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, ... Blood 136, 40-41, 2020 | 36 | 2020 |
| A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas PA Riedell, C Walling, LJ Nastoupil, M Pennisi, RT Maziarz, JP McGuirk, ... Biology of Blood and Marrow Transplantation 26 (3), S41-S42, 2020 | 36 | 2020 |
| Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Blood 136, 1-3, 2020 | 35 | 2020 |
